Clinical Trials

About Lundbeck’s Clinical Trials

Lundbeck’s purpose is to restore brain health and we are grateful to the patients, healthy volunteers, families, and clinics that participate in our clinical trials. Each individual’s participation contributes to our understanding of disease and has the potential to benefit patients around the world.

Disclosure of Clinical Trial Information

Lundbeck registers clinical trial protocols and discloses the results of clinical trials, regardless of outcome, in a publicly accessible clinical trial registry, ClinicalTrials.gov. In addition, clinical trial protocols and results information submitted by Lundbeck to the EudraCT database is made publicly available by the European Medicines Agency (EMA) via its clinical trial registry

 

Clinical trial reports will be accessible on the EMA’s page for clinical trial data in accordance with EMA POLICY/0070. Non-interventional studies may also be disclosed if, for example, they are considered to provide important safety data. 


Lundbeck will seek to ensure that disclosure of clinical trial information follows the IFPMA, EFPIA, JPMA, and PhRMA joint position paper “Disclosure of Clinical Trial Information via Clinical Trial Registries and Databases”, the Declaration of Helsinki, and other relevant clinical trial disclosure requirements.


Lundbeck respects the privacy of the relationship between patients and healthcare professionals and is committed to ensuring that the process of scientific publication and clinical trial data sharing do not breach patient confidentiality.

More from lundbeck

Pipeline

Discover our projects and compounds in development. 

Publications

Our policy for scientific publications and responsible clinical data sharing.

Corporate News

All the Latest on Lundbeck.